**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Paolo Milani, Department of Molecular Medicine, University of Pavia, Pavia, Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

**Main Body of the Abstract**
The combination of daratumumab and pomalidomide is effective in relapsed/refractory (R/R) multiple myeloma. In June 2021, we started a phase II clinical trial to evaluate the efficacy and safety of this combination in daratumumab naïve R/R AL amyloidosis (NCT04895917). The primary endpoint was the rate of good quality [(i.e. complete response (CR) + very good partial response (VGPR)] at the completion of 6 cycles. Patients had to be previously exposed to alkylators and/or proteasome inhibitor. They received up to 6 cycles of daratumumab (1800 mg sc once weekly for 3 cycles and subsequently every other week), pomalidomide (4 mg from day 1-21, on 28 days cycles) and weekly dexamethasone (20+20 mg).
Twenty-seven patients were enrolled (Table). Three patients are still on treatment at the data lock. Twenty (74%) patients completed the planned treatment. Overall, 25 patients experienced at least 1 grade 3-4 adverse events: neutropenia (20, 74%), rash (3, 11%), fluid retention (2, 7%). Overall, 23 (85%) patients achieved a hematologic response [13 (48%) VGPR and 9 (33%) CR] at cycle 6. Hematologic response was reached at day 8 in 20/23 (86%) cases. Minimal residual disease by next generation flow cytometry (sensitivity 10-6) was negative in 3/7 evaluated patients in CR. Cardiac responses were reached in 7/21 (33%) and renal response in 10/14 (85%) at cycle 6.
Daratumumab and pomalidomide is rapidly and highly effective in daratumumab-naïve patients with R/R AL amyloidosis. Hematologic adverse events are frequent but do not affect treatment delivery.



A phase II study of daratumumab and pomalidomide in previously treated patients with AL amyloidosis OA10 (#466)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.